Brain Cholesterol Synthesis and Metabolism is Progressively Disturbed in the R6/1 Mouse Model of Huntington’s Disease: A Targeted GC-MS/MS Sterol Analysis
Restricted accessResearch articleFirst published online
Brain Cholesterol Synthesis and Metabolism is Progressively Disturbed in the R6/1 Mouse Model of Huntington’s Disease: A Targeted GC-MS/MS Sterol Analysis
Cholesterol has essential functions in neurological processes that require tight regulation of synthesis and metabolism. Perturbed cholesterol homeostasis has been demonstrated in Huntington’s disease, however the exact role of these changes in disease pathogenesis is not fully understood.
Objective:
This study aimed to comprehensively examine changes in cholesterol biosynthetic precursors, metabolites and oxidation products in the striatum and cortex of the R6/1 transgenic mouse model of Huntington’s disease. We also aimed to characterise the progression of the physical phenotype in these mice.
Methods:
GC-MS/MS was used to quantify a broad range of sterols in the striatum and cortex of R6/1 and wild type mice at 6, 12, 20, 24 and 28 weeks of age. Motor dysfunction was assessed over 28 weeks using the RotaRod and the hind-paw clasping tests.
Results:
24(S)-Hydroxycholesterol and 27-hydroxycholesterol were the major cholesterol metabolites that significantly changed in R6/1 mice. These changes were specifically localised to the striatum and were detected at the end stages of the disease. Cholesterol synthetic precursors (lathosterol and lanosterol) were significantly reduced in the cortex and striatum by 6 weeks of age, prior to the onset of motor dysfunction, as well as the cognitive and affective abnormalities previously reported. Elevated levels of desmosterol, a substrate of delta(24)-sterol reductase (DHCR24), were also detected in R6/1 mice at the end time-point. Female R6/1 mice exhibited a milder weight loss and hind paw clasping phenotype compared to male R6/1 mice, however, no difference in the brain sterol profile was detected between sexes.
Conclusion:
Several steps in cholesterol biosynthetic and metabolic pathways are differentially altered in the R6/1 mouse brain as the disease progresses and this is most severe in the striatum. This provides further insights into early molecular mediators of HD onset and disease progression and identifies candidate molecular targets for novel therapeutic approaches.
RosasHD, KoroshetzWJ, ChenYI, SkeuseC, VangelM, CudkowiczME, CaplanK, MarekK, SeidmanLJ, MakrisN, JenkinsBG, GoldsteinJM. Evidence for more widespread cerebral pathology in early HD: An MRI-based morphometric analysis. Neurology. 2003;60(10):1615–20.
3.
KegelKB, SappE, AlexanderJ, ValenciaA, ReevesP, LiX, MassoN, SobinL, AroninN, DiFigliaM. Polyglutamine expansion in huntingtin alters its interaction with phospholipids. J Neurochem. 2009;110(5):1585–97.
4.
del ToroD, XifroX, PolA, HumbertS, SaudouF, CanalsJM, AlberchJ. Altered cholesterol homeostasis contributes to enhanced excitotoxicity in Huntington’s disease. J Neurochem. 2010;115(1):153–67.
5.
SipioneS, RigamontiD, ValenzaM, ZuccatoC, ContiL, PritchardJ, KooperbergC, OlsonJM, CattaneoE. Early transcriptional profiles in huntingtin-inducible striatal cells by microarray analyses. Hum Mol Genet. 2002;11(17):1953–65.
6.
ValenzaM, RigamontiD, GoffredoD, ZuccatoC, FenuS, JamotL, StrandA, TarditiA, WoodmanB, RacchiM, MariottiC, Di DonatoS, CorsiniA, BatesG, PrussR, OlsonJM, SipioneS, TartariM, CattaneoE. Dysfunction of the cholesterol biosynthetic pathway in Huntington’s disease. J Neurosci. 2005;25(43):9932–9.
7.
ValenzaM, LeoniV, TarditiA, MariottiC, BjorkhemI, Di DonatoS, CattaneoE. Progressive dysfunction of the cholesterol biosynthesis pathway in the R6/2 mouse model of Huntington’s disease. Neurobiol Dis. 2007;28(1):133–42.
8.
ValenzaM, LeoniV, KarasinskaJM, PetriccaL, FanJ, CarrollJ, PouladiMA, FossaleE, NguyenHP, RiessO, MacDonaldM, WellingtonC, DiDonatoS, HaydenM, CattaneoE. Cholesterol defect is marked across multiple rodent models of Huntington’s disease and is manifest in astrocytes. J Neurosci. 2010;30(32):10844–50.
9.
FanQW, YuW, GongJS, ZouK, SawamuraN, SendaT, YanagisawaK, MichikawaM. Cholesterol-dependent modulation of dendrite outgrowth and microtubule stability in cultured neurons. J Neurochem. 2002;80(1):178–90.
HayashiH, CampenotRB, VanceDE, VanceJE. Glial lipoproteins stimulate axon growth of central nervous system neurons in compartmented cultures. J Biol Chem. 2004;279(14):14009–15.
12.
WassifCA, MaslenC, Kachilele-LinjewileS, LinD, LinckLM, ConnorWE, SteinerRD, PorterFD. Mutations in the human sterol Δ7-reductase gene at 11q12-13 cause Smith-Lemli-Opitz syndrome. Am J Hum Genet. 1998;63(1):55–62.
13.
WaterhamHR, KosterJ, RomeijnGJ, HennekamRC, VrekenP, AnderssonHC, FitzPatrickDR, KelleyRI, WandersRJ. Mutations in the 3beta-hydroxysterol Delta24-reductase gene cause desmosterolosis, an autosomal recessive disorder of cholesterol biosynthesis. Am J Hum Genet. 2001;69(4):685–94.
14.
BrownMS, GoldsteinJL. A proteolytic pathway that controls the cholesterol content of membranes, cells, and blood. Proc Natl Acad Sci U S A. 1999;96:11041–11048.
LuuW, Hart-SmithG, SharpeLJ, BrownAJ. The terminal enzymes of cholesterol synthesis, DHCR24 and DHCR7, interact physically and functionally. J Lipid Res. 2015;56(4):888–97.
17.
ValenzaM, CarrollJB, LeoniV, BertramLN, BjorkhemI, SingarajaRR, Di DonatoS, LutjohannD, HaydenMR, CattaneoE. Cholesterol biosynthesis pathway is disturbed in YAC128 mice and is modulated by huntingtin mutation. Hum Mol Genet. 2007;16(18):2187–98.
18.
LutjohannD, BreuerO, AhlborgG, NennesmoI, SidenI, DiczfalusyU, BjorkhemI. Cholesterol homeostasis in human brain: Evidence for an age-dependent flux of 24S-hydroxycholesterol from the brain into the circulation. Proc Natl Acad Sci U S A. 1996;93:9799–9804.
19.
BjorkhemI, LutjohannD, DiczfalusyU, StahleL, AhlborgG, WahrenJ. Cholesterol homeostasis in human brain: Turnover of 24S-hydroxycholesterol and evidence for a cerebral origin of most of this oxysterol in the circulation. J Lipid Res. 1998;39(8):1594–1600.
20.
LundEG, GuileyardoJM, RussellDW. cDNA cloning of cholesterol 24-hydroxylase, a mediator of cholesterol homeostasis in the brain. Proc Natl Acad Sci U S A. 1999;96(13):7238–43.
21.
LeoniV, MariottiC, TabriziSJ, ValenzaM, WildEJ, HenleySMD, HobbsNZ, MandelliML, GrisoliM, BjorkhemI, CattaneoE, Di DonatoS. Plasma 24S-hydroxycholesterol and caudate MRI in pre-manifest and early Huntingtons disease. Brain. 2008;131:2851–2859.
22.
LeoniV, LongJD, MillsJA, Di DonatoS, PaulsenJS, groupP-Hs. Plasma 24S-hydroxycholesterol correlation with markers of Huntington disease progression. Neurobiol Dis. 2013;55:37–43.
23.
KolschH, LutjohannD, LudwigM, SchulteA, PtokU, JessenF, von BergmannK, RaoML, MaierW, HeunR. Polymorphism in the cholesterol 24S-hydroxylase gene is associated with Alzheimer’s disease. Mol Psychiatry. 2002;7(8):899–902.
PapassotiropoulosA, StrefferJR, TsolakiM, SchmidS, ThalD, NicosiaF, IakovidouV, MaddalenaA, LutjohannD, GhebremedhinE, HegiT, PaschT, TraxlerM, BruhlA, BenussiL, BinettiG, BraakH, NitschRM, HockC. Increased brain beta-amyloid load, phosphorylated tau, and risk of Alzheimer disease associated with an intronic CYP46 polymorphism. Arch Neurol. 2003;60(1):29–35.
26.
TianG, KongQ, LaiL, Ray-ChaudhuryA, LinCL. Increased expression of cholesterol 24S-hydroxylase results in disruption of glial glutamate transporter EAAT2 association with lipid rafts: A potential role in Alzheimer’s disease. J Neurochem. 2010;113(4):978–89.
27.
MartinKO, BudaiK, JavittNB. Cholesterol and 27-hydroxycholesterol 7 alpha-hydroxylation: Evidence for two different enzymes. J Lipid Res [Research Support, U.S. Gov’t, P.H.S.]. 1993;34(4):581–8.
28.
LundE, AnderssonO, ZhangJ, BabikerA, AhlborgG, DiczfalusyU, EinarssonK, SjovallJ, BjorkhemI. Importance of a novel oxidative mechanism for elimination of intracellular cholesterol in humans. Arteriosclerosis, thrombosis, and vascular biology [Research Support, Non-U.S. Gov’t]. 1996;16(2):208–12.
29.
HeverinM, MeaneyS, LutjohannD, DiczfalusyU, WahrenJ, BjorkhemI. Crossing the barrier: Net flux of 27-hydroxycholesterol into the human brain. J Lipid Res. 2005;46(5):1047–1052.
30.
MeaneyS, HeverinM, PanzenboeckU, EkstromL, AxelssonM, AnderssonU, DiczfalusyU, PikulevaI, WahrenJ, SattlerW, BjorkhemI. Novel route for elimination of brain oxysterols across the blood-brain barrier: Conversion into 7alpha-hydroxy-3-oxo-4-cholestenoic acid. J Lipid Res. 2007;48(4):944–51.
31.
ShafaatiM, MarutleA, PetterssonH, Lovgren-SandblomA, OlinM, PikulevaI, WinbladB, NordbergA, BjorkhemI. Marked accumulation of 27-hydroxycholesterol in the brains of Alzheimer’s patients with the Swedish APP 670/671 mutation. J Lipid Res. 2011;52(5):1004–10.
32.
HeverinM, BogdanovicN, LutjohannD, BayerT, PikulevaI, BretillonL, DiczfalusyU, WinbladB, BjorkhemI. Changes in the levels of cerebral and extracerebral sterols in the brain of patients with Alzheimer’s disease. J Lipid Res. 2004;45(1):186–93.
33.
SubbaraoKV, RichardsonJS, AngLC. Autopsy samples of Alzheimer’s cortex show increased peroxidation in vitro. J Neurochem. 1990;55(1):342–5.
JennerA, RenM, RajendranR, NingP, HuatBT, WattF, HalliwellB. Zinc supplementation inhibits lipid peroxidation and the development of atherosclerosis in rabbits fed a high cholesterol diet. Free Radic Biol Med. 2007;42(4):559–66.
36.
IulianoL, MichelettaF, NatoliS, CorradiniSG, IappelliM, EliseiW, GiovannelliL, VioliF, DiczfalusyU. Measurement of oxysterols and alpha-tocopherol in plasma and tissue samples as indices of oxidant stress status. Anal Biochem. 2003;312(2):217–223.
37.
IulianoL, MonticoloR, StrafaceG, ZulloS, GalliF, BoazM, QuattrucciS. Association of cholesterol oxidation and abnormalities in fatty acid metabolism in cystic fibrosis. Am J Clin Nutr. 2009;90(3):477–84.
38.
RodriguezIR, FlieslerSJ. Photodamage generates 7-keto- and 7-hydroxycholesterol in the rat retina via a free radical-mediated mechanism. Photochem Photobiol. 2009;85(5):1116–25.
39.
MangiariniL, SathasivamK, SellerM, CozensB, HarperA, HetheringtonC, LawtonM, TrottierY, LehrachH, DaviesSW, BatesGP. Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell. 1996;87(3):493–506.
40.
MazarakisNK, Cybulska-KlosowiczA, GroteH, PangT, Van DellenA, KossutM, BlakemoreC, HannanAJ. Deficits in experience-dependent cortical plasticity and sensory-discrimination learning in presymptomatic Huntington’s disease mice. J Neurosci. 2005;25(12):3059–66.
41.
NithianantharajahJ, BarkusC, MurphyM, HannanAJ. Gene-environment interactions modulating cognitive function and molecular correlates of synaptic plasticity in Huntington’s disease transgenic mice. Neurobiol Dis. 2008;29(3):490–504.
42.
GroteHE, BullND, HowardML, vanDellen A, BlakemoreC, BartlettPF, HannanAJ. Cognitive disorders and neurogenesis deficits in Huntington’s disease mice are rescued by fluoxetine. Eur J Neurosci. 2005;22(8):2081–8.
43.
PangTY, DuX, ZajacMS, HowardML, HannanAJ. Altered serotonin receptor expression is associated with depression-related behavior in the R6/1 transgenic mouse model of Huntington’s disease. Hum Mol Genet. 2009;18(4):753–66.
44.
ZhangY, AppelkvistEL, KristenssonK, DallnerG. The lipid compositions of different regions of rat brain during development and aging. Neurobiol Aging. 1996;17(6):869–75.
45.
DietschyJM, TurleySD. Thematic review series: Brain Lipids. Cholesterol metabolism in the central nervous system during early development and in the mature animal. J Lipid Res. 2004;45(8):1375–97.
46.
BartzokisG, LuPH, TishlerTA, FongSM, OluwadaraB, FinnJP, HuangD, BordelonY, MintzJ, PerlmanS. Myelin breakdown and iron changes in Huntington’s disease: Pathogenesis and treatment implications. Neurochem Res. 2007;32(10):1655–64.
47.
ThelenKM, FalkaiP, BayerTA, LutjohannD. Cholesterol synthesis rate in human hippocampus declines with aging. Neurosci Lett. 2006;403(1-2):15–9.
48.
MarulloM, ValenzaM, LeoniV, CacciaC, ScarlattiC, De MarioA, ZuccatoC, Di DonatoS, CarafoliE, CattaneoE. Pitfalls in the detection of cholesterol in Huntington’s disease models. PLoS Curr. 2012;4:e505886e9a1968.
49.
LodiR, SchapiraAH, MannersD, StylesP, WoodNW, TaylorDJ, WarnerTT. Abnormal in vivo skeletal muscle energy metabolism in Huntington’s disease and dentatorubropallidoluysian atrophy. Ann Neurol. 2000;48(1):72–6.
50.
ChenCM, WuYR, ChengML, LiuJL, LeeYM, LeePW, SoongBW, ChiuDT. Increased oxidative damage and mitochondrial abnormalities in the peripheral blood of Huntington’s disease patients. Biochem Biophys Res Commun. 2007;359(2):335–40.
51.
Perez-SeverianoF, RiosC, SegoviaJ. Striatal oxidative damage parallels the expression of a neurological phenotype in mice transgenic for the mutation of Huntington’s disease. Brain Res. 2000;862(1-2):234–7.
52.
MoralesLM, EstevezJ, SuarezH, VillalobosR, Chacin de BonillaL, BonillaE. Nutritional evaluation of Huntington disease patients. The American Journal of Clinical Nutrition. 1989;50(1):145–50.
53.
SanbergPR, FibigerHC, MarkRF. Body weight and dietary factors in Huntington’s disease patients compared with matched controls. The Medical Journal of Australia [Comparative Study]. 1981;1(8):407–9.
54.
CliffordJJ, DragoJ, NatoliAL, WongJY, KinsellaA, WaddingtonJL, VaddadiKS. Essential fatty acids given from conception prevent topographies of motor deficit in a transgenic model of Huntington’s disease. Neuroscience [Research Support, Non-U.S. Gov’t]. 2002;109(1):81–8.
55.
NaverB, StubC, MollerM, FengerK, HansenAK, HasholtL, SorensenSA. Molecular and behavioral analysis of the R6/1 Huntington’s disease transgenic mouse. Neuroscience. 2003;122(4):1049–57.
